Cargando…
Validation of the OncoHepa test, a multigene expression profile test, and the tumor marker-volume score to predict postresection outcome in small solitary hepatocellular carcinomas
PURPOSE: OncoHepa test is a multigene expression profile test developed for assessment of hepatocellular carcinoma (HCC) prognosis. Multiplication of α-FP, des-γ-carboxy prothrombin (DCP) and tumor volume (TV) gives the α-FP-DCP-volume (ADV) score, which is also developed for assessment of HCC progn...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Surgical Society
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255750/ https://www.ncbi.nlm.nih.gov/pubmed/30505821 http://dx.doi.org/10.4174/astr.2018.95.6.303 |
_version_ | 1783374008248434688 |
---|---|
author | Ha, Su-Min Hwang, Shin Park, Jin Young Lee, Young-Joo Kim, Ki-Hun Song, Gi-Won Jung, Dong-Hwan Yu, Yun-Suk Kim, Jinpyo Lee, Kyoung-Jin Tak, Eunyoung Park, Yo-Han Lee, Sung-Gyu |
author_facet | Ha, Su-Min Hwang, Shin Park, Jin Young Lee, Young-Joo Kim, Ki-Hun Song, Gi-Won Jung, Dong-Hwan Yu, Yun-Suk Kim, Jinpyo Lee, Kyoung-Jin Tak, Eunyoung Park, Yo-Han Lee, Sung-Gyu |
author_sort | Ha, Su-Min |
collection | PubMed |
description | PURPOSE: OncoHepa test is a multigene expression profile test developed for assessment of hepatocellular carcinoma (HCC) prognosis. Multiplication of α-FP, des-γ-carboxy prothrombin (DCP) and tumor volume (TV) gives the α-FP-DCP-volume (ADV) score, which is also developed for assessment of HCC prognosis. METHODS: The predictive powers of OncoHepa test and ADV score were validated in 35 patients who underwent curative hepatic resection for naïve solitary HCCs ≤5 cm. RESULTS: Median tumor diameter was 3.0 cm. Tumor recurrence and patient survival rates were 28.6% and 100% at 1 year, 48.6% and 82.9% at 3 years, and 54.3% and 71.4% at 5 years, respectively. The site of first tumor recurrence was the remnant liver in 18, lung in 1, and the peritoneum in 1. All patients with HCC recurrence received locoregional treatment. OncoHepa test showed marginal prognostic significance for tumor recurrence and patient survival. ADV score at 4log also showed marginal prognostic difference with respect to tumor recurrence and patient survival. Combination of these 2 tests resulted in greater prognostic significance for both tumor recurrence (P = 0.046) and patient survival (P = 0.048). CONCLUSION: Both OncoHepa test and ADV score have considerably strong prognostic power, thus individual and combined findings of OncoHepa test and ADV score will be helpful to guide postresection surveillance in patients with solitary HCCs ≤5 cm. |
format | Online Article Text |
id | pubmed-6255750 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | The Korean Surgical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-62557502018-12-01 Validation of the OncoHepa test, a multigene expression profile test, and the tumor marker-volume score to predict postresection outcome in small solitary hepatocellular carcinomas Ha, Su-Min Hwang, Shin Park, Jin Young Lee, Young-Joo Kim, Ki-Hun Song, Gi-Won Jung, Dong-Hwan Yu, Yun-Suk Kim, Jinpyo Lee, Kyoung-Jin Tak, Eunyoung Park, Yo-Han Lee, Sung-Gyu Ann Surg Treat Res Original Article PURPOSE: OncoHepa test is a multigene expression profile test developed for assessment of hepatocellular carcinoma (HCC) prognosis. Multiplication of α-FP, des-γ-carboxy prothrombin (DCP) and tumor volume (TV) gives the α-FP-DCP-volume (ADV) score, which is also developed for assessment of HCC prognosis. METHODS: The predictive powers of OncoHepa test and ADV score were validated in 35 patients who underwent curative hepatic resection for naïve solitary HCCs ≤5 cm. RESULTS: Median tumor diameter was 3.0 cm. Tumor recurrence and patient survival rates were 28.6% and 100% at 1 year, 48.6% and 82.9% at 3 years, and 54.3% and 71.4% at 5 years, respectively. The site of first tumor recurrence was the remnant liver in 18, lung in 1, and the peritoneum in 1. All patients with HCC recurrence received locoregional treatment. OncoHepa test showed marginal prognostic significance for tumor recurrence and patient survival. ADV score at 4log also showed marginal prognostic difference with respect to tumor recurrence and patient survival. Combination of these 2 tests resulted in greater prognostic significance for both tumor recurrence (P = 0.046) and patient survival (P = 0.048). CONCLUSION: Both OncoHepa test and ADV score have considerably strong prognostic power, thus individual and combined findings of OncoHepa test and ADV score will be helpful to guide postresection surveillance in patients with solitary HCCs ≤5 cm. The Korean Surgical Society 2018-12 2018-11-26 /pmc/articles/PMC6255750/ /pubmed/30505821 http://dx.doi.org/10.4174/astr.2018.95.6.303 Text en Copyright © 2018, the Korean Surgical Society http://creativecommons.org/licenses/by-nc/4.0/ Annals of Surgical Treatment and Research is an Open Access Journal. All articles are distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Ha, Su-Min Hwang, Shin Park, Jin Young Lee, Young-Joo Kim, Ki-Hun Song, Gi-Won Jung, Dong-Hwan Yu, Yun-Suk Kim, Jinpyo Lee, Kyoung-Jin Tak, Eunyoung Park, Yo-Han Lee, Sung-Gyu Validation of the OncoHepa test, a multigene expression profile test, and the tumor marker-volume score to predict postresection outcome in small solitary hepatocellular carcinomas |
title | Validation of the OncoHepa test, a multigene expression profile test, and the tumor marker-volume score to predict postresection outcome in small solitary hepatocellular carcinomas |
title_full | Validation of the OncoHepa test, a multigene expression profile test, and the tumor marker-volume score to predict postresection outcome in small solitary hepatocellular carcinomas |
title_fullStr | Validation of the OncoHepa test, a multigene expression profile test, and the tumor marker-volume score to predict postresection outcome in small solitary hepatocellular carcinomas |
title_full_unstemmed | Validation of the OncoHepa test, a multigene expression profile test, and the tumor marker-volume score to predict postresection outcome in small solitary hepatocellular carcinomas |
title_short | Validation of the OncoHepa test, a multigene expression profile test, and the tumor marker-volume score to predict postresection outcome in small solitary hepatocellular carcinomas |
title_sort | validation of the oncohepa test, a multigene expression profile test, and the tumor marker-volume score to predict postresection outcome in small solitary hepatocellular carcinomas |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255750/ https://www.ncbi.nlm.nih.gov/pubmed/30505821 http://dx.doi.org/10.4174/astr.2018.95.6.303 |
work_keys_str_mv | AT hasumin validationoftheoncohepatestamultigeneexpressionprofiletestandthetumormarkervolumescoretopredictpostresectionoutcomeinsmallsolitaryhepatocellularcarcinomas AT hwangshin validationoftheoncohepatestamultigeneexpressionprofiletestandthetumormarkervolumescoretopredictpostresectionoutcomeinsmallsolitaryhepatocellularcarcinomas AT parkjinyoung validationoftheoncohepatestamultigeneexpressionprofiletestandthetumormarkervolumescoretopredictpostresectionoutcomeinsmallsolitaryhepatocellularcarcinomas AT leeyoungjoo validationoftheoncohepatestamultigeneexpressionprofiletestandthetumormarkervolumescoretopredictpostresectionoutcomeinsmallsolitaryhepatocellularcarcinomas AT kimkihun validationoftheoncohepatestamultigeneexpressionprofiletestandthetumormarkervolumescoretopredictpostresectionoutcomeinsmallsolitaryhepatocellularcarcinomas AT songgiwon validationoftheoncohepatestamultigeneexpressionprofiletestandthetumormarkervolumescoretopredictpostresectionoutcomeinsmallsolitaryhepatocellularcarcinomas AT jungdonghwan validationoftheoncohepatestamultigeneexpressionprofiletestandthetumormarkervolumescoretopredictpostresectionoutcomeinsmallsolitaryhepatocellularcarcinomas AT yuyunsuk validationoftheoncohepatestamultigeneexpressionprofiletestandthetumormarkervolumescoretopredictpostresectionoutcomeinsmallsolitaryhepatocellularcarcinomas AT kimjinpyo validationoftheoncohepatestamultigeneexpressionprofiletestandthetumormarkervolumescoretopredictpostresectionoutcomeinsmallsolitaryhepatocellularcarcinomas AT leekyoungjin validationoftheoncohepatestamultigeneexpressionprofiletestandthetumormarkervolumescoretopredictpostresectionoutcomeinsmallsolitaryhepatocellularcarcinomas AT takeunyoung validationoftheoncohepatestamultigeneexpressionprofiletestandthetumormarkervolumescoretopredictpostresectionoutcomeinsmallsolitaryhepatocellularcarcinomas AT parkyohan validationoftheoncohepatestamultigeneexpressionprofiletestandthetumormarkervolumescoretopredictpostresectionoutcomeinsmallsolitaryhepatocellularcarcinomas AT leesunggyu validationoftheoncohepatestamultigeneexpressionprofiletestandthetumormarkervolumescoretopredictpostresectionoutcomeinsmallsolitaryhepatocellularcarcinomas |